Lineage Cell Therapeutics, Inc. (LCTX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Lineage Cell Therapeutics reported revenue of $14.6M, up 53.2% from $9.5M the year before. Net income was -$63.5M (a -436.5% net margin), or -$0.28 per diluted share. Gross margin was -251.6% and operating margin was -251.6%. Operating activities generated -$18.9M of cash, leaving -$19.4M of free cash flow. At fiscal year end, Lineage Cell Therapeutics held $112.6M in total assets against $69.2M in total liabilities, including $40.8M of cash and equivalents.
Open the full interactive Lineage Cell Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Lineage Cell Therapeutics Key Stats
| Share Price | $0.91 |
|---|---|
| Market Cap | $237.9M |
| Revenue YoY Growth | +53.2% |
| 52-Week Range | $0.90 – $1.96 |
| Shares Outstanding | 249.5 million (basic, 2026 Q2) |
Lineage Cell Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.8M | $4.3M | $14.7M | $8.9M | $9.5M | $14.6M |
| Cost of Goods Sold | — | — | — | — | $31.0M | $51.2M |
| Gross Profit | $1.4M | $2.9M | $14.0M | $8.3M | $9.2M | -$36.6M |
| Operating Income | -$26.4M | -$49.2M | -$22.5M | -$24.7M | -$21.5M | -$36.6M |
| Pre-Tax Income | -$21.9M | -$43.3M | -$25.8M | -$23.3M | -$18.6M | -$68.6M |
| Income Tax | -$1.2M | -$251,000 | $541,000 | -$1.8M | $0 | -$5.3M |
| Net Income | -$20.6M | -$43.0M | -$26.3M | -$21.5M | -$18.6M | -$63.5M |
| Diluted EPS | -$0.14 | -$0.26 | — | -$0.12 | -$0.09 | -$0.28 |
Lineage Cell Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $3.7M | $6.6M | $1.7M | $1.1M |
| Net Income | -$29.8M | $851,000 | -$4.8M | $1.5M |
| Diluted EPS | -$0.13 | $0.00 | -$0.03 | -$0.03 |
Lineage Cell Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.6M | $55.7M | $11.4M | $35.4M | $45.8M | $40.8M |
| Current Assets | $44.0M | $111.5M | $60.0M | $38.4M | $51.0M | $59.2M |
| Total Assets | $107.9M | $174.5M | $123.7M | $101.0M | $113.2M | $112.6M |
| Current Liabilities | $7.8M | $47.1M | $19.0M | $18.0M | $14.0M | $11.4M |
| Total Liabilities | $12.8M | $83.6M | $51.7M | $39.0M | $36.2M | $69.2M |
| Shareholders' Equity | $96.2M | $92.2M | $73.3M | $63.4M | $78.4M | $44.5M |
Lineage Cell Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$19.8M | -$23.6M | $1.1M | -$28.6M | -$23.1M | -$18.9M |
| Cash From Investing | $13.0M | $9.7M | -$46.2M | $46.4M | -$2.3M | -$13.5M |
| Cash From Financing | $29.9M | $36.9M | $1.6M | $6.4M | $35.9M | $26.9M |
| Free Cash Flow | -$19.8M | -$23.9M | $646,000 | -$29.2M | -$23.7M | -$19.4M |
Figures from Lineage Cell Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Lineage Cell Therapeutics financials page for every line item.
Lineage Cell Therapeutics Company Profile
| Ticker | LCTX |
|---|---|
| Exchange | NYSE |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Carlsbad, California |
| Incorporated in | California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000876343 |
Frequently Asked Questions
What was Lineage Cell Therapeutics' revenue in fiscal 2025?
Lineage Cell Therapeutics (LCTX) reported revenue of $14.6M for fiscal 2025.
What is Lineage Cell Therapeutics' annual revenue history?
Lineage Cell Therapeutics' annual revenue by fiscal year: 2020: $1.8M; 2021: $4.3M; 2022: $14.7M; 2023: $8.9M; 2024: $9.5M; 2025: $14.6M.
What was Lineage Cell Therapeutics' net income in fiscal 2025?
Lineage Cell Therapeutics reported net income of -$63.5M for fiscal 2025.
What was Lineage Cell Therapeutics' earnings per share (EPS) in fiscal 2025?
Lineage Cell Therapeutics' diluted EPS was -$0.28 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Lineage Cell Therapeutics generate in fiscal 2025?
Lineage Cell Therapeutics generated -$19.4M of free cash flow in fiscal 2025.
What was Lineage Cell Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Lineage Cell Therapeutics reported revenue of $1.1M.
How many shares of Lineage Cell Therapeutics are outstanding?
Lineage Cell Therapeutics reported a weighted average of 249.5 million basic shares outstanding in 2026 Q2.
What is Lineage Cell Therapeutics' market cap?
Based on its latest closing price, Lineage Cell Therapeutics (LCTX) has a market capitalization of about $237.9M.
When does Lineage Cell Therapeutics' fiscal year end?
Lineage Cell Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Lineage Cell Therapeutics headquartered?
Lineage Cell Therapeutics lists its business address in Carlsbad, California in its SEC filings.
Lineage Cell Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →